论文部分内容阅读
CA4磷酸酯(Combretastatin A4phosphate,CA4P)系从非洲植物中提取出的血管损伤剂(Vascular Disrupting Ag_ents,VDA)类抗肿瘤药前体,合成后的CA4P与CA4相比水溶性增强,有关CA4P制剂已进行了一系列离体及临床研究。CA4P不同于传统微管蛋白抑制剂,在小于1/10最大耐受剂量(MTD)时
CA4P is a kind of anticancer drug precursor extracted from African plants. Compared with CA4P, CA4P has better water solubility, A series of in vitro and clinical studies were conducted. CA4P is different from traditional tubulin inhibitors at less than 1/10 of the maximal tolerated dose (MTD)